- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06332508
Pulsed Electromagnetic Fields (PEMFs) - A Highly Selective Breast CAncer Treatment pLatform (PASCAL)
Pulsed Electromagnetic Fields (PEMFs) - A Highly Selective Breast CAncer Treatment pLatform (PASCAL), First-in-man Phase 1 Safety Trials
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Si Jing, Joline Lim
- Phone Number: 67737888
- Email: joline_sj_lim@nuhs.edu.sg
Study Locations
-
-
-
Singapore, Singapore, 119074
- Recruiting
- National University Hospital
-
Contact:
- Joline Si Jing Lim
- Phone Number: 69082222
- Email: joline_sj_lim@nuhs.edu.sg
-
Principal Investigator:
- Joline Si Jing Lim
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed breast carcinoma of any subtype (any estrogen receptor, progesterone receptor and HER2 receptor status)
- ECOG 0-1.
- Non-metastatic disease for which surgery of curative intent is planned upfront or after completion of neoadjuvant chemotherapy
Adequate organ function including the following:
Bone marrow:
- Absolute neutrophil (segmented and bands) count (ANC) >= 1.5 x 10^9/L
- Platelets >= 100 x 10^9/L
- Hemoglobin >= 8 x 10^9/L
Hepatic:
- Bilirubin <= 1.5 x upper limit of normal (ULN),
- ALT or AST <= 2.5x ULN, (or <=5 X with liver metastases)
Renal:
- Creatinine <= 1.5x ULN
- Signed informed consent from subject or legal representative.
- Able to comply with study-related procedures.
Exclusion Criteria:
- Pregnancy.
- Breast feeding.
- Presence of fungating breast tumor or open wound in breast planned for PEMF.
- Active bleeding disorder or bleeding site.
- Second primary malignancy that is clinically detectable at the time of consideration for study enrollment.
- Major surgery within 28 days prior to study administration.
- Non-healing wound.
- Active infection that in the opinion of the investigator would compromise the subject's ability to tolerate therapy.
- History of significant neurological or mental disorder, including seizures or dementia.
- Serious concomitant disorders that would compromise the safety of the subject or compromise the subject's ability to complete the study, at the discretion of the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PEMFs prior to surgery
During the study period, subjects will receive local magnetic therapy (PEMFs).
The study aims to enrol subjects in 4 groups - in dose level 1 and 2 (subjects who do not need chemotherapy prior to surgery), PEMF will be administered prior to surgery;
|
Device: PEMFs PEMFs treatment can be delivered up to 7 days prior to day of surgery (dose levels 1-2) or anthracycline-based chemotherapy (dose levels 3-4) to allow subject flexibility of timing and decrease the need for multiple visits. A research staff will be assigned to be with subject during the duration of PEMFs to monitor for any side effects during treatment. |
Experimental: PEMFs prior to chemotherapy
In dose level 3 and 4 (subjects who require chemotherapy), PEMF will be administered prior to chemotherapy.
|
Device: PEMFs PEMFs treatment can be delivered up to 7 days prior to day of surgery (dose levels 1-2) or anthracycline-based chemotherapy (dose levels 3-4) to allow subject flexibility of timing and decrease the need for multiple visits. A research staff will be assigned to be with subject during the duration of PEMFs to monitor for any side effects during treatment. Drug: Anthracycline-based chemotherapy (doxorubicin, cyclophosphamide) At dose levels 3 and 4, two cohorts will be opened: the first cohort will undergo surgical resection immediately after completion of anthracycline-based chemotherapy, and the second cohort will undergo taxane-based chemotherapy following completion of anthracycline-based chemotherapy. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE 5.0
Time Frame: up to 6 months
|
Toxicity to treatment as assessed by Common Terminology Criteria for Adverse Events 5.0. Grade 1-5 refer to the severity of the adverse event with higher grade indicating greater severity. Grade 3 and above will be considered severe. A dose limiting toxicity will be defined as Grade 3 or above toxicity of the following: a) pain in breast where PEMF was applied
|
up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment response as assessed by clinical measurement of tumor size using calipers
Time Frame: up to 6 months
|
Subjects should have documented the size of the tumor through clinical measurement using calipers at each assessment visit.
Wherever possible, documentation of radiological size based on mammogram, ultrasound or magnetic resonance imaging should also be recorded.
|
up to 6 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Si Jing, Joline Lim, National University Hospital, Singapore
Publications and helpful links
General Publications
- Tai YK, Chan KKW, Fong CHH, Ramanan S, Yap JLY, Yin JN, Yip YS, Tan WR, Koh APF, Tan NS, Chan CW, Huang RYJ, Li JZ, Frohlich J, Franco-Obregon A. Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach. Front Oncol. 2022 Jan 24;11:783803. doi: 10.3389/fonc.2021.783803. eCollection 2021. Erratum In: Front Oncol. 2022 Apr 20;12:892408.
- Haidinger R, Bauerfeind I. Long-Term Side Effects of Adjuvant Therapy in Primary Breast Cancer Patients: Results of a Web-Based Survey. Breast Care (Basel). 2019 Apr;14(2):111-116. doi: 10.1159/000497233. Epub 2019 Feb 15.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022/00406
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Pulsed electromagnetic fields (PEMFs)
-
Pamukkale UniversityCompleted
-
The Danish Research Centre for Chemical SensitivitiesAage Bangs FondCompletedMultiple Chemical SensitivityDenmark
-
University of Padova, School of Dental MedicineCompletedPain | Oral Surgery | Third Molar Extraction
-
University of MessinaCompleted
-
National University Hospital, SingaporeNational University, SingaporeRecruitingObesity | Type 2 DiabetesSingapore
-
National University Hospital, SingaporeNational University, SingaporeTerminatedCognitive Change | Cerebral HemodynamicsSingapore
-
University of California, San DiegoCompletedPhantom Limb Pain | Residual Limb PainUnited States
-
University of California, San DiegoActive, not recruitingPostoperative Pain, AcuteUnited States
-
University of California, San DiegoEnrolling by invitation
-
Charite University, Berlin, GermanySeibersdorf Labor GmbHSuspended